FSHR Antibody Engineering for Targeted Cancer and Infertility Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antibodies against the follicle stimulating hormone receptor (FSHR) for therapeutic and diagnostic applications, as well as methods for their production and use.
Innovation Solution
Development of isolated antibodies or antigen binding fragments with specific binding affinity to FSHR, including chimeric and humanized variants, and their use in pharmaceutical compositions for treating diseases such as cancer and infertility, as well as for contraception, with potential administration routes including intravenous, intra-articular, and subcutaneous delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies against FSHR are developed for therapeutic applications, then treatment efficacy for cancer and infertility is improved, but manufacturing complexity and production costs increase
Solution Approach 1:
The antibody molecule is segmented into distinct functional regions: variable domains (VH and VL) containing CDRs for antigen binding, and constant domains (CH and CL) for effector functions. This segmentation allows independent optimization of binding affinity and therapeutic activity, improving treatment efficacy while enabling modular manufacturing approaches that reduce complexity
Solution Approach 2:
The anti-FSHR antibody is designed with universal applicability across multiple therapeutic indications including cancer treatment, infertility therapy, and contraception. The single molecular entity can target FSHR in different tissue contexts (ovary, testis, tumor cells), providing multi-functional therapeutic benefits from one manufactured product, thereby improving efficacy across indications without proportionally increasing manufacturing complexity
2Reliability
If specific binding affinity to FSHR is enhanced through CDR optimization, then therapeutic effectiveness is improved, but antibody production difficulty increases
Solution Approach 1:
The CDR regions (CDR1, CDR2, CDR3 of VH and VL) are optimized with specific amino acid sequences to achieve high binding affinity to FSHR epitopes, while the framework regions maintain standard immunoglobulin structures. This local optimization of only the critical binding regions improves therapeutic effectiveness without requiring complex modifications throughout the entire antibody molecule, thereby reducing production difficulty
Solution Approach 2:
The antibody design specifies precise amino acid sequences in the CDR regions (e.g., VH CDR1: QYQAPYTL, VH CDR2: DQW, VH CDR3: EHWY) to optimize binding parameters. These parameter changes are confined to specific positions in the sequence, allowing for targeted production strategies that focus resources on the critical binding regions rather than the entire molecule, thus improving affinity while managing production complexity
Data Source
AI summary
The present invention relates to an isolated antibody or antigen binding fragment thereof that bind specifically to the Follicle Stimulating Hormone Receptor (FSHR). Also provided are methods for treating a disease in a subject comprising administering to the subject an isolated antibody or antibody fragment thereof that binds FSHR.